Clinical trials recruiting in Nevada

Phase breakdown

Cities in Nevada

Conditions recruiting in Nevada

Recruiting trials in Nevada

• 10,000 Step Club: Community Walking Program for People with Parkinson's Disease
  NCT06605183 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years to 85 Years · Sex: All (male and female)
• 52-week Open Label Safety-Tolerability Study
  NCT07369154 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
  NCT07332000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
  NCT07094516 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female)
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
  NCT07459647 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
  NCT07483073 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
  NCT07745907 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female)
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
  NCT06680830 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
  NCT06830629 · Phase: Phase 2 · Ages: 18 Years to 68 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
  NCT06226883 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
  NCT07113522 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
  NCT07599813 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
  NCT07711418 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
  NCT05862272 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: Female
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
  NCT07647328 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
  NCT07221227 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
  NCT06764940 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
  NCT06112418 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
  NCT06664619 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
  NCT07029399 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
  NCT06285643 · Phase: Phase 2 · Ages: 45 Years to 75 Years · Sex: All (male and female)
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female)
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
  NCT06765668 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
  NCT07602582 · Phase: Phase 3 · Ages: 55 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
  NCT06119581 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
  NCT06576271 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
  NCT07258849 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
  NCT07483099 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
  NCT07142356 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study of NTX-1472 in Social Anxiety Disorder
  NCT07323784 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
  NCT06389136 · Phase: Phase 3 · Ages: 18 Years to 63 Years · Sex: All (male and female)
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
  NCT06581328 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
  NCT05967689 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  NCT06793397 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
  NCT07288138 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT06568939 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
  NCT07005102 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT04928846 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
  NCT06884865 · Phase: Phase 2 · Ages: 45 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
  NCT06651567 · Phase: Phase 2 · Ages: 55 Years and older · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
  NCT06887192 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female)
• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
  NCT06929273 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
  NCT06724640 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
  NCT06749457 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female)
• A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
  NCT07219173 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07522073 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
  NCT07776509 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
  NCT06612268 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)

Showing 100 of 292 recruiting trials.

Common questions

How many clinical trials are recruiting in Nevada?

292 recruiting trials have at least one study site in Nevada.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.